Effects of albiglutide on myocardial infarction and ischaemic heart disease outcomes in patients with type 2 diabetes and cardiovascular disease in the Harmony Outcomes trial.

Autor:	Krychtiuk KA; Duke Clinical Research Institute, Durham, NC 27701, USA., Marquis-Gravel G; Duke Clinical Research Institute, Durham, NC 27701, USA., Murphy S; Duke Clinical Research Institute, Durham, NC 27701, USA., Alexander KP; Duke Clinical Research Institute, Durham, NC 27701, USA., Chiswell K; Duke Clinical Research Institute, Durham, NC 27701, USA., Green JB; Duke Clinical Research Institute, Durham, NC 27701, USA., Leiter LA; Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, ON M5B 1W8, Canada., Lopes RD; Duke Clinical Research Institute, Durham, NC 27701, USA., Del Prato S; Section on Diabetes, Department of Clinical and Experimental Medicine, University of Pisa, and Sant'Anna School of Advanced Studies, 56126 Pisa, Italy., Jones WS; Duke Clinical Research Institute, Durham, NC 27701, USA., McMurray JJV; British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, Glasgow G12 8TA, UK., Hernandez AF; Duke Clinical Research Institute, Durham, NC 27701, USA., Granger CB; Duke Clinical Research Institute, Durham, NC 27701, USA.
Jazyk:	angličtina
Zdroj:	European heart journal. Cardiovascular pharmacotherapy [Eur Heart J Cardiovasc Pharmacother] 2024 Jul 16; Vol. 10 (4), pp. 279-288.
DOI:	10.1093/ehjcvp/pvae006
Abstrakt:	Aims: Large outcome trials have demonstrated cardiovascular benefits of selected glucagon-like peptide-1 (GLP-1) receptor agonists. We examined coronary disease outcomes in the Harmony Outcomes trial of the GLP-1 receptor agonist albiglutide. Methods and Results: Harmony Outcomes was an event-driven, multicenter, double-blind, and placebo-controlled trial involving 9463 patients >40 years of age with type-2 diabetes and established atherosclerotic cardiovascular disease. It tested the effects of albiglutide on the occurrence of a composite primary endpoint, consisting of cardiovascular death, myocardial infarction (MI), or stroke. Within this post-hoc analysis, the effects of albiglutide on MI subtypes and other ischaemic endpoints were analysed.During the median-follow up of 1.6 years, a total of 421 patients (4.5%) experienced at least one MI, with 72 patients having more than one event. Treatment with albiglutide reduced both first events [hazard ratio (HR) 0.75 (0.62-0.91)] and overall events [HR 0.75 (0.61-0.91)] as well as first type 1 [HR 0.73 (0.57-0.92)] and type 2 myocardial infarctions [HR 0.65 (0.46-0.92)]. The effect of albiglutide treatment was consistent for ST-segment elevation [HR 0.69 (0.38-1.26)] and non-ST elevation (HR 0.86 (0.66-1.2) MI. Conclusion: Treatment with the GLP-1 receptor agonist albiglutide resulted in a 25% relative risk reduction in MI that was consistent for type of infarction and presence or absence of ST elevation. Our findings add novel information about the effects of GLP-1 receptor agonists on ischaemic events in patients with type 2 diabetes. (© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu